Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
03:11:46 EST Sun 08 Feb 2026
Enter Symbol
or Name
USA
CA



Q:RHHBY - ROCHE HOLDINGS AG SPN ADR EACH REP 0.125 GENUS - https://roche.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
RHHBY - Qnot subscribed57.70+0.5791.06,159.9353,4757,72556.90  57.98  56.73558.40  34.7516:38:37Jan 2715 min RT 2¢

Recent Trades - Last 10 of 7725
Time ETExPriceChangeVolume
16:38:37Q57.700.579200
16:36:08Q57.700.579568
16:05:23Q57.700.57936
16:03:38Q57.670.549528
16:03:37Q57.700.57919,406
16:03:17Q57.700.57919,300
16:03:12Q57.700.57919,480
16:00:20Q57.590.46910
16:00:20Q57.650.52912
15:59:59Q57.700.57928

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-02-07 15:40U:RHHBYNews ReleaseGenentech's Fenebrutinib Is the First Investigational Medicine in Over a Decade That Reduces Disability Progression in Primary Progressive Multiple Sclerosis (PPMS)
2026-01-27 01:10U:RHHBYNews ReleaseGenentech Announces Positive Phase II Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People Living With Obesity
2026-01-20 10:30U:RHHBYNews ReleaseGenentech More than Doubles Investment in Holly Springs, North Carolina Manufacturing Facility
2025-12-22 01:00U:RHHBYNews ReleaseFDA Approves Genentech's Lunsumio VELO(TM) for Subcutaneous Use in Relapsed or Refractory Follicular Lymphoma
2025-12-16 08:30U:RHHBYNews ReleaseRoche announces U.S. launch of next-generation cobas 6800/8800 systems and software, enhancing laboratory efficiency and testing capabilities
2025-12-10 08:20U:RHHBYNews ReleaseGenentech's Giredestrant Reduced Risk of Invasive Disease Recurrence or Death by 30% in ER-positive Early-Stage Breast Cancer
2025-12-08 16:30U:RHHBYNews ReleaseGenentech Presents Lunsumio Data Showing Potential Across Earlier Treatment Lines in Indolent and Aggressive Lymphomas
2025-11-18 01:10U:RHHBYNews ReleaseGenentech's Giredestrant Becomes the First Oral SERD to Show Superior Invasive Disease-Free Survival in Early Breast Cancer
2025-11-12 01:00U:RHHBYNews ReleaseMillennials at highest risk of missing crucial cervical cancer screenings, finds survey commissioned by Roche
2025-11-10 01:10U:RHHBYNews ReleaseGenentech's Fenebrutinib Shows Unprecedented Positive Phase III Results as the Potential First and Only BTK Inhibitor in Both Relapsing and Primary Progressive Multiple Sclerosis
2025-11-03 09:00U:RHHBYNews ReleaseGenentech to Present New Data From Its Broad and Innovative Hematology Portfolio at ASH 2025
2025-11-03 01:00U:RHHBYNews ReleasePositive Phase III Data for Genentech's Gazyva Show Significant Reduction in Disease Activity for Systemic Lupus Erythematosus
2025-10-28 02:00U:RHHBYNews ReleasePositive Phase III Results for Genentech's Gazyva in Children and Young Adults With Idiopathic Nephrotic Syndrome
2025-10-20 01:05U:RHHBYNews ReleaseGenentech's Tecentriq Showed Significant Overall and Disease-Free Survival Benefits in Bladder Cancer With ctDNA-Guided Treatment
2025-10-20 01:00U:RHHBYNews ReleaseFDA Approves Genentech's Gazyva for the Treatment of Lupus Nephritis
2025-10-18 01:05U:RHHBYNews ReleaseGenentech's Phase III evERA Data Showed Giredestrant Significantly Improved Progression-Free Survival in People With ER-Positive Advanced Breast Cancer
2025-10-17 16:20U:RHHBYNews ReleaseGenentech Presents New Phase III Pivotal Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss
2025-10-16 11:45U:RHHBYNews ReleaseGenentech Expands Xofluza(TM) Access and Affordability for Upcoming Flu Season With Direct-to-Patient Launch
2025-10-13 09:00U:RHHBYNews ReleaseRoche's Elecsys(TM) pTau181 becomes the only FDA-cleared blood test for use in primary care to rule out Alzheimer's-related amyloid pathology
2025-10-13 01:05U:RHHBYNews ReleaseGenentech Data at ESMO 2025 Showcase Advances in Science and Cancer Care Across Multiple Tumor Types